论文部分内容阅读
目的:沐舒坦采用静脉滴注及雾化吸入治疗新生儿肺炎的安全性观察。方法:本次研究对象均从从东莞市凤岗镇凤岗医院2013年6月-2014年6月收治的新生儿肺炎患儿中抽取62例,分为两组,各31例,单纯给予对照组患儿静脉滴注沐舒坦治疗,研究组则采用静脉滴注联合雾化吸入沐舒坦,观察两组的安全性。结果:治疗后,研究组各项临床症状消失时间、平均住院天数等,与对照组比较,差异有统计学意义(P<0.05),研究组患儿临床总有效率为97.77%,与对照组患儿的77.42%比较,差异具有统计学意义(P<0.05)。结论:应用静脉滴注结合雾化吸入沐舒坦治疗新生儿肺炎的临床效果较好,安全性较高。
Objective: To observe the safety of mucosolvan by intravenous drip and nebulized inhalation in the treatment of neonatal pneumonia. Methods: The subjects were from 62 cases of neonates with pneumonia admitted from Fenggang Hospital, Fenggang Town, Dongguan City from June 2013 to June 2014. The patients were divided into two groups of 31 cases Group intravenous infusion of ambroxol treatment group, the study group was intravenous infusion combined inhalation of mucosolvan, observe the safety of the two groups. Results: After treatment, the disappearance time of clinical symptoms, average days of hospitalization and so on in the study group were significantly different from those in the control group (P <0.05). The total clinical effective rate in the study group was 97.77% Children with 77.42%, the difference was statistically significant (P <0.05). Conclusion: The clinical effect of intravenous drip combined with inhalation of mucosolvan in the treatment of neonatal pneumonia is better and the safety is higher.